Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synthetic Circulating Cell-free DNA as Quality Control Materials for Somatic Mutation Detection in Liquid Biopsy for Cancer.

Clinical chemistry - 1 Sept 2017

Zhang Rui, Peng Rongxue, Li Ziyang, Gao Peng, Jia Shiyu, Yang Xin, Ding Jiansheng, Han Yanxi, Xie Jiehong, Li Jinming

Abstract excerpt

BACKGROUND: Detection of somatic genomic alterations in tumor-derived cell-free DNA (cfDNA) in the plasma is challenging owing to the low concentrations of cfDNA, variable detection methods, and complex workflows. Moreover, no proper quality control materials are available currently. METHODS: We developed a set of synthetic cfDNA quality control materials (SCQCMs) containing spike-in cfDNA on the basis of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Biopsy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to ALK gene

Share to EML4 gene

Share to Genetic Variation

Share to HEK293 Cells

Share to Observer Variation

Source

Identifiers

PMID: 28720677
DOI: 10.1373/clinchem.2017.272559

Genes

ALK
EML4
EGFR
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synthetic Circulating Cell-free DNA as Quality Control Materials for Somatic Mutation Detection in Liquid Biopsy for Cancer.PMID 28720677Read ↗

Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assaySemantic proximity Read ↗

Clinical Testing for Tumor Cell-Free DNA: College of American Pathologists Proficiency Programs Reveal Practice Trends.Semantic proximity Read ↗

Benchmarking fragmentation-derived artificial cfDNA reference standardsSemantic proximity Read ↗

Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA.Semantic proximity Read ↗

Development of a nine-variant reference material panel to standardize cell-free DNA detection.Semantic proximity Read ↗

Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA MeasurementsSemantic proximity Read ↗

Cell-Free DNA, Tumor Molecular Concordance, and Clinical Correlates of Patients with Cancer Treated in a Large Community Health Care NetworkSemantic proximity Read ↗

Collection of cell-free DNA for genomic analysis of solid tumors in a clinical laboratory settingSemantic proximity Read ↗

Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assaySemantic proximity Read ↗

Advancing quality-control for NGS measurement of actionable mutations in circulating tumor DNASemantic proximity Read ↗

Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging TechnologiesSemantic proximity Read ↗

Quantitative PCR-Based Method to Assess Cell-Free DNA Quality, Adjust Input Mass, and Improve Next-Generation Sequencing Assay Performance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.